Ketamine Providers in Massachusetts
19 providers across 14 cities
Massachusetts has 19 ketamine therapy providers across 14 cities. The most common provider types are psychiatry practice, ketamine infusion clinic, med spa & aesthetic. Providers in Massachusetts commonly treat depression, anxiety, ptsd. Top cities include Brookline, Cambridge, Belmont, Beverly, Boston.
Ketamine Therapy in Massachusetts
Massachusetts is a national leader in ketamine therapy, anchored by world-class research institutions like Massachusetts General Hospital and Harvard Medical School. The state's 24 ketamine therapy providers offer IV infusions, intramuscular injections, and FDA-approved Spravato treatments across the greater Boston area and beyond. With pioneering clinical trials demonstrating ketamine's effectiveness for treatment-resistant depression and a supportive regulatory framework, Massachusetts patients have access to evidence-based ketamine care from some of the country's most experienced practitioners.
Massachusetts ranks 12th nationally with 19 ketamine therapy providers, averaging 1.4 providers per city. The largest provider category is psychiatry practice (78.9% of providers). Brookline leads the state with 5 providers.
State Regulations
Massachusetts regulates ketamine under the Board of Registration in Medicine, which oversees physician prescribing of controlled substances. Ketamine is a Schedule III drug requiring DEA registration and active state medical licensure. The MA Board of Registration in Pharmacy adopted a specific compounded ketamine policy in May 2023 (revised December 2023) permitting pharmacies to compound ketamine nasal spray.
Insurance & Medicaid Coverage
MassHealth covers FDA-approved Spravato (esketamine nasal spray) for treatment-resistant depression, though prior authorization is required. Spravato must be administered in a certified healthcare setting under medical supervision per FDA REMS requirements. Off-label IV ketamine infusions are generally not covered by MassHealth and remain an out-of-pocket expense for most patients.
Telehealth Options
Massachusetts permits telehealth prescribing of controlled substances in accordance with state and federal regulations (101 CMR 329). Under DEA telemedicine flexibilities extended through December 31, 2026, practitioners can prescribe Schedule III-V substances like ketamine via video visits without a prior in-person exam.
Cost of Ketamine Therapy
IV ketamine infusions in Massachusetts typically cost $475–$750 per session. Boston-area clinics command premium pricing due to high operating costs. Massachusetts General Hospital charges $550 per infusion. Academic medical centers and suburban clinics may vary. A standard initial series of 6 infusions runs $2850–$4500. Spravato (esketamine) may be partially or fully covered by insurance.
Mental Health Access
Massachusetts has multiple mental health HPSA designations with only 24.65% of mental health care needs currently met. HRSA data indicates the state needs 16 additional mental health practitioners to remove all shortage designations, reflecting gaps primarily in rural western counties and underserved urban populations. Massachusetts has approximately 0.34 ketamine providers per 100,000 residents.
Frequently Asked Questions
- Yes, ketamine therapy is legal in Massachusetts. It is prescribed off-label by licensed physicians and nurse practitioners with DEA registration and active state medical licenses. The MA Board of Registration in Medicine oversees prescribing standards, and the Board of Registration in Pharmacy has established specific compounding policies for ketamine nasal spray.
- MassHealth and most private insurers in Massachusetts cover FDA-approved Spravato (esketamine nasal spray) with prior authorization for treatment-resistant depression. However, off-label IV ketamine infusions are typically not covered and cost $475 to $750 per session out of pocket.
- Massachusetts permits telehealth prescribing of controlled substances under 101 CMR 329. Federal DEA telemedicine flexibilities, extended through December 2026, allow providers to prescribe ketamine via video consultation without a prior in-person visit. However, IV infusions and Spravato administration still require in-person clinical visits.